Schouw & Co (SCHO) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
23 Nov, 2025Executive summary
Q2 2025 delivered stable but slightly lower revenue and EBITDA amid persistent market uncertainty, leveraging a diversified portfolio and strong mitigation measures.
Strong operational cash flow and net working capital improvements, with net interest-bearing debt reduced by DKK 1.3 billion year-over-year.
FX impacts on financial items, but underlying interest rate costs and financial gearing improved.
Evaluation of a potential BioMar IPO continues, with a banking syndicate established and possible listing in H1 2026.
Financial highlights
Q2 2025 revenue was DKK 8,525m, down 2% year-over-year; EBITDA was DKK 706m, down 4%; EBIT was DKK 428m, down 6%.
Profit before tax for Q2 was DKK 338m, down 2% year-over-year; profit for the period was DKK 247m.
Cash flow from operating activities improved 61% to DKK 542m; net interest-bearing debt decreased by DKK 1,278m year-over-year to DKK 5,435m.
Earnings per share for Q2 was DKK 10.18, down 3% year-over-year.
Group EBITDA margin impacted by one-off costs; Q2 EBITDA margin: 8.3%; EBIT margin: 5.0%; EBT margin: 4.0%.
Outlook and guidance
Full-year 2025 revenue guidance narrowed to DKK 33.7–35.7bn; EBITDA guidance narrowed to DKK 2,830–3,090m, including DKK 100m in one-off restructuring costs.
BioMar, HydraSpecma, and Fibertex Personal Care raised their full-year revenue and/or EBITDA guidance; GPV and Borg Automotive narrowed or lowered EBITDA guidance due to market softness and one-off costs.
Depreciation and amortisation expected at DKK 1,140m; net financial items expected to be a DKK 360m expense.
Latest events from Schouw & Co
- Record cash flow and EBITDA growth in most segments, with improved leverage and strong 2026 outlook.SCHO
Q4 20255 Mar 2026 - EBITDA guidance raised as margin gains offset revenue decline amid market headwinds.SCHO
Q2 20241 Feb 2026 - Revenue and EBITDA fell, but margins and cash flow held; BioMar IPO and cost cuts in focus.SCHO
Q3 202415 Jan 2026 - EBITDA rose 3% to DKK 2.93bn despite a 7% revenue drop, with strong cash flow and lower debt.SCHO
Q4 202423 Dec 2025 - Q1 2025 revenue up 1%, EBITDA down 13%, guidance maintained, BioMar IPO prep advances.SCHO
Q1 202529 Nov 2025 - EBITDA rose 5% despite a 4% revenue drop, with narrowed guidance and ongoing restructuring.SCHO
Q3 202512 Nov 2025